{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-005356","form_type":"8-K","ticker":null,"cik":"0001310527","company_name":"QSAM Biosciences, Inc.","filed_at":"2024-02-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.729986+00:00","generated_at":"2026-06-06T05:26:19.748639+00:00","sec_items":["1.01","5.03","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"QSAM Biosciences to be acquired by Telix for ~$33.1M shares plus up to $90M CVRs","bullets":["Telix will acquire QSAM via two-step merger; total base consideration ~$33.1M in Telix shares (at $7.5745/share).","QSAM stockholders receive 0.876 Telix shares per pre-reverse-split share (est. $6.63/share value).","Up to $90M in contingent value rights (CVRs) on regulatory/commercial milestones over 10 years.","Reverse stock split (1:1000 to 1:2000) to be effected before close; all preferred converted.","Lock-up agreements for officers/directors on Telix shares received for 12 months post-close."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-005356","json":"https://secwatch.observer/filing/0001493152-24-005356.json","markdown":"https://secwatch.observer/filing/0001493152-24-005356.md","text":"https://secwatch.observer/filing/0001493152-24-005356.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1310527/000149315224005356/0001493152-24-005356-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1310527/000149315224005356/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T05:26:19.748639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7e3e630e02318501ac3047659deca8b8ca623776","claim":"QSAM Biosciences, Inc.: Proposed reverse stock split requiring amendment to Amended and Restated Certificate of Incorporation.","evidence_excerpt":"Upon the QSAM Board’s approval of the Reverse Split ratio, QSAM shall file an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1310527/000149315224005356/0001493152-24-005356-index.htm","confidence":0.4,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"}],"fact_type":"governance_change"},{"claim_id":"4f343f7a9a34a065728fde3db8a969ea9a49f9eb","claim":"QSAM Biosciences, Inc. entered into Agreement and Plan of Merger with Telix Pharmaceuticals Limited, Cyclone Merger Sub I, Inc., Cyclone Merger Sub II, Inc., and David H. Clarke (effective 2024-02-07).","evidence_excerpt":"On February 7, 2024, QSAM Biosciences, Inc. (“QSAM”) entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Telix Pharmaceuticals Limited","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1310527/000149315224005356/0001493152-24-005356-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"merger"},{"label":"Counterparty","value":"Telix Pharmaceuticals Limited, Cyclone Merger Sub I, Inc., Cyclone Merger Sub II, Inc., and David H. Clarke"},{"label":"Effective","value":"2024-02-07"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}